AstraZeneca Will Get Humira Royalty Revenue Through CAT Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca's acquisition of Cambridge Antibody Technology will give the firm royalty revenues from human monoclonal antibody technologies already licensed out by CAT, including Abbott's rheumatoid arthritis therapy Humira (adalimumab)
You may also be interested in...
AstraZeneca Shifts Abandoned GI Developmental Compounds To New Affiliate
New company Albireo will be financed initially with $27 million from three growth capital firms.
AstraZeneca Shifts Abandoned GI Developmental Compounds To New Affiliate
New company Albireo will be financed initially with $27 million from three growth capital firms.
HGS/GSK On Track To Initiate Lymphostat-B Phase III Study In 2006
Full Phase II study results show promise in treatment of lupus even though Lymphostat-B did not meet primary endpoints, the firm says.